

### Remarks

Support for Amendments to the Specification:

It was recently discovered that 14 compounds were incorrectly identified as exhibiting a  $K_i$  value of about 20 nM or less for at least two of the following receptors: D2, 5HT1B and 5HT2A or an effective  $K_i$  value at about 10 nM or less for each of said receptors. These 14 compounds are removed from the list of compounds said to exhibit this activity by the amendments to the Specification provided herein.

A recurring typographical error is also corrected by placing a “(“ in front of four compounds. The “(“ is underlined and also bolded to help identify it.

The amendments do not add new matter.

### Conclusion

Applicants believe that this case is in condition for allowance, early notice of which would be appreciated. The amendment under § 312 made minor claim amendments as discussed in the support for said amendment; early entry is requested as part of this submission. If Examiner has any questions concerning this request, Examiner is invited to contact the below-signed attorney. As provided in the accompanying documents, please charge any required fee payment or credit any overpayment to Charge Account 16-1445.

Respectfully submitted,

\_\_\_\_\_/Mary J. Hosley/\_\_\_\_\_  
Mary J. Hosley, Attorney, Registration No. 48,324

Date: 26 May 2006

Pfizer, Inc  
150 East 42nd Street, Floor 5  
New York, NY 10017-5612  
Telephone No. 212.733-0460  
Telefax No. 212.573-1939